At a press conference at ESMO 2014, Prof Stahel presents the results of a phase II trial which found that about 20% of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1) that is associated with poorer outcomes.

Read the news story for more.

ecancer's filming at ESMO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.